Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905377 | 0.81 | HRH3 (0.51) | HRH3GABRA1GABRB2TP53MAPT | |
| SCHEMBL9628115 | 0.77 | HRH3 (0.57) | HRH3GABRA1GABRB2TP53MTNR1A | |
| SCHEMBL9458993 | 0.77 | HRH3 (0.47) | HRH3GABRA1GABRB2TP53MAPT | |
| SCHEMBL10257134 | 0.76 | HRH3 (0.60) | HRH3GABRA1GABRB2TP53MAPT | |
| SCHEMBL17761389 | 0.76 | HRH3 (0.56) | HRH3GABRA1GABRB2TP53MAPT | |
| SCHEMBL13802286 | 0.75 | FFAR1 (0.56) | HRH3GABRA1GABRB2MTNR1AGLS | |
| SCHEMBL9629907 | 0.75 | MTNR1A (0.52) | HRH3GABRA1GABRB2TP53MTNR1A | |
| SCHEMBL9117533 | 0.74 | HRH3 (0.63) | HRH3GABRA1GABRB2TP53MTNR1A | |
| SCHEMBL10256487 | 0.73 | HRH3 (0.59) | HRH3GABRA1GABRB2TP53MTNR1A | |
| Methylamine SCHEMBL10700886 | 0.73 | HRH3 (0.59) | HRH3GABRA1GABRB2MTNR1AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841925-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-6482956-B2 | FOR THERAPY OF CARDIOVASCULAR, CEREBROVASCULAR, RESPIRATORY AND RENAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20020072614-A1 | Endothelin receptor antagonists | LUENGO JUAN IGNACIO (US) | 2002-06-13 | — | — | US | disclosed |
| US-6353116-B1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0841925-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6096897-A | NOVEL 1,2,3-TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5969151-A | PYRAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958968-A | CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0841925-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004772-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072614-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | HRH3 542/4885GABRA1 161/4885GABRB2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.